Literature DB >> 23177277

What causes false-negative PET findings for solid-type lung cancer?

Shingo Iwano1, Shinji Ito, Kenichi Tsuchiya, Katsuhiko Kato, Shinji Naganawa.   

Abstract

BACKGROUND: To investigate possible causes for false-negative findings on PET scans for solid-type lung cancers, we retrospectively compared PET findings to clinical and pathological features using multivariate analysis.
METHODS: We reviewed PET/CT records, clinical records, preoperative thin-section CT images, and postoperative pathological records and selected only solid-type primary lung cancers with lesions ≤ 40 mm in diameter that had been definitively diagnosed by surgical resection. PET images with SUVmax of ≥ 2.5 were considered PET-positive. Logistic regression analysis was used to identify independent predictors of PET-positive or negative among five factors: body weight, blood glucose level, lesion size, location, and histological classification.
RESULTS: A total of 187 solid-type primary lung cancers were selected. Forty lesions (21.4%) were judged as PET-negative and 147 lesions (78.6%) were judged as PET-positive. Multivariate logistic analysis for the 187 lesions revealed that lesion size (p<0.001) and histological tumour type (p<0.001) were significant factors for determining whether PET findings were negative.
CONCLUSIONS: Among solid-type lung cancers, lesion size and histopathological findings were significantly associated with FDG uptake. In particular, it warrants attention that lesions ≤ 2 cm and bronchioloalveolar carcinoma and well-differentiated adenocarcinoma have a tendency for negative PET findings.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23177277     DOI: 10.1016/j.lungcan.2012.10.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

1.  Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements.

Authors:  Mahsa Eskian; Abass Alavi; MirHojjat Khorasanizadeh; Benjamin L Viglianti; Hans Jacobsson; Tara D Barwick; Alipasha Meysamie; Sun K Yi; Shingo Iwano; Bohdan Bybel; Federico Caobelli; Filippo Lococo; Joaquim Gea; Antonio Sancho-Muñoz; Jukka Schildt; Ebru Tatcı; Constantin Lapa; Georgia Keramida; Michael Peters; Raef R Boktor; Joemon John; Alexander G Pitman; Tomasz Mazurek; Nima Rezaei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

2.  18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET.

Authors:  Tadashi Watabe; Hayato Ikeda; Shushi Nagamori; Pattama Wiriyasermkul; Yoko Tanaka; Sadahiro Naka; Yasukazu Kanai; Kohei Hagiwara; Masanao Aoki; Eku Shimosegawa; Yoshikatsu Kanai; Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-22       Impact factor: 9.236

3.  Consistency and prognostic value of preoperative staging and postoperative pathological staging using 18F-FDG PET/MRI in patients with non-small cell lung cancer.

Authors:  Akiko Kajiyama; Kimiteru Ito; Hirokazu Watanabe; Sunao Mizumura; Shun-Ichi Watanabe; Yasushi Yatabe; Tatsuya Gomi; Masahiko Kusumoto
Journal:  Ann Nucl Med       Date:  2022-10-20       Impact factor: 2.258

4.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

5.  Evaluation of lung cancer by enhanced dual-energy CT: association between three-dimensional iodine concentration and tumour differentiation.

Authors:  Shingo Iwano; Rintaro Ito; Hiroyasu Umakoshi; Shinji Ito; Shinji Naganawa
Journal:  Br J Radiol       Date:  2015-09-02       Impact factor: 3.039

Review 6.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

7.  A retrospective study analyzing missed diagnosis of lung metastases at their early stages on computed tomography.

Authors:  Huai Chen; Suidan Huang; Qingsi Zeng; Min Zhang; Zhiwen Ni; Xiaoling Li; Xiaoyin Xu
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

8.  Phantom and clinical assessment of small pulmonary nodules using Q.Clear reconstruction on a silicon-photomultiplier-based time-of-flight PET/CT system.

Authors:  Zhifang Wu; Binwei Guo; Bin Huang; Xinzhong Hao; Ping Wu; Bin Zhao; Zhixing Qin; Jun Xie; Sijin Li
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.379

9.  Adenocarcinoma with BAC features presented as the nonsolid nodule is prone to be false-negative on 18F-FDG PET/CT.

Authors:  Hu-bing Wu; Lijuan Wang; Quan-shi Wang; Yan-jian Han; Hong-sheng Li; Wen-lan Zhou; Ying Tian
Journal:  Biomed Res Int       Date:  2015-03-24       Impact factor: 3.411

Review 10.  FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Nobuyuki Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-04-03       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.